Simcere Pharmaceutical Group Receives China Approval to Begin Clinical Trials for SIM0610 Bispecific Antibody-Drug Conjugate
I'm PortAI, I can summarize articles.
Simcere Pharmaceutical Group Ltd. has received approval from China's National Medical Products Administration to begin clinical trials for its bispecific antibody-drug conjugate, SIM0610. This drug targets EGFR and cMET and will be tested in patients with advanced solid tumors, marking a significant milestone in Simcere's oncology drug development.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments